AXS-05 Demonstrates Efficacy and Manageable Adverse Effects in Major Depressive Disorder Treatment
February 12th 2025A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.
SPN-820 Shows Rapid and Significant Improvement in Major Depressive Disorder Symptoms
February 12th 2025A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.